Sirolimus-based immunosuppression: Present state of the art

Journal of Nephrology

Volumn 17, Issue SUPPL. 8, 2004, Pages

  Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Immunosuppression; Maintenance therapy; Rapamycin; Sirolimus

Indexed keywords

CYCLOSPORIN; RAPAMYCIN; STEROID; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ARTHROPATHY; BLOOD VESSEL OCCLUSION; BONE MARROW SUPPRESSION; DISEASE COURSE; DRUG EXPOSURE; DRUG MONITORING; GRAFT RECIPIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LIPID METABOLISM; NUCLEOTIDE METABOLISM; PROPHYLAXIS; PSORIASIS; REVIEW; SIDE EFFECT; WOUND HEALING IMPAIRMENT; DRUG EFFECT; DRUG INTERACTION; GRAFT REJECTION; KIDNEY; KIDNEY TRANSPLANTATION;

DRUG INTERACTIONS; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; SIROLIMUS;

EID: 16644400352     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335.
2. Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DJ, Thiru S. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2: 227.
3. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17: 877.
4. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattstrom C, Charpentier B. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036.
5. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattstrom C, Lebranchu Y, Vialtel P. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
6. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Negre E, Burke JT, Groth CG; Sirolimus European Renal Transplant Study Group. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436.
7. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche H-U, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040.
8. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J, for the Rapamune Study Group. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial. Transplantation 1999; 68: 1526.
9. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. For the Rapamune U.S. Study Group. Lancet 2000; 356: 194.
10. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. For the Rapamune Global Study Group. Transplantation 2001; 71: 271.
11. Kahan BD, Kramer WG. Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin Pharmacol Ther 2001; 70: 74.
12. Kahan BD, Knight R, Schoenberg L, Pobielski J, Kerman RH, Mahalati K, Yakupoglu Y, Aki FT, Katz S, Van Buren CT. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003; 35 (suppl 3): S25-34.
13. Yakupoglu Y, Kahan BD. Low incidence of malignancy among renal transplant recipients treated with a sirolimus (SRL)-cyclosporine (CsA) regimen (Abstract 135). Am J Transplant 2003; 3: 186.
14. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Is there an effect of induction immunosuppression on PTLD and graft/patient survival after kidney transplantation? (Abstract 1598). Am J Transplant 2003; 3: 562.
15. Kahan BD, Pescovitz M, Ghan G, Neylan J, Julian B, Katz SM, Van Buren, CT. One-year outcome after steroid withdrawal from a sirolimus-cyclosporine- prednisone regimen in cadaver-and living-donor recipients (Abstract 658). XVII Annual Meeting of the American Society for Transplant Physicians 1998: 243.
16. Mahalati K, Kahan BD. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine combination therapy. Transplant Proc 2001; 33: 1270.
17. Knight RJ, Csapo Z, Benavides-Viveros C, Schoenberg L, Kerman RH, Podder H, Katz SM, Van Buren CT, Kahan BD. Five-year follow-up after prednisone withdrawal using sirolimus-cyclosporine immunosuppression for renal transplantation (Abstract 516). Am J Transplant 2004; 4: 300.
18. Kahan BD, Camardo JS. Rapamycin: Clinical results and future opportunities. Transplantation 2001; 72: 1181.
19. Dijoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53: 507.
20. Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311.
21. Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou TC, Kahan BD. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059.
22. Stepkowski SM, Kahan BD. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival. Transplant Proc 1991; 23: 3262.
23. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, Valeri R, Levine JS. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281: F693-706.
24. Inman SR, Davis NA, Olson KM, Lukaszek VA, McKinley MR, Seminerio JL. Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury. Urology 2003; 62: 750.
25. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998; 66: 1697.
26. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
27. Hong JC, Kahan BD. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at high risk for delayed graft function. Transplantation 2001; 71: 1320.
28. Knight RJ, Kerman RH, Schoenberg L, Podder H, Van Buren CT, Katz S, Kahan BD. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low versus high risk for delayed graft function. Transplantation 2004; 78: 904.
29. McTaggart RA, Gottlieb D, Brooks J, Bacchetti P, Roberts JP, Tomlanovich S, Feng S. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416.
30. Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14: 1037.
31. Lawsin L, Light JA. Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. Transplantation 2003; 75: 157.
32. Kahan BD, Schoenberg LP, Christensen L, Podbielski J, Port FK. A concentration-controlled regimen of high sirolimus exposure supports functional recovery of human renal allografts from deceased donors (Abstract). XX International Congress of the Transplantation Society, September 5-10, Vienna, Austria 2004.
33. Kahan BD. Established immunosuppressive drugs: Clinical and toxic effects. In: Kahan BD, Ponticelli C, eds. Principles and practice of renal transplantation. London: Martin Dunitz; 2000: 349.
34. Napoli KL, Wang ME, Stepkowski SM, Kahan BD. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interactions. Ther Drug Monit 1998; 20: 123.
35. Zimmerman J, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37: 405.
36. Keane WF. Lipids and progressive renal disease: the cardio-renal link. Am J Kidney Dis 1999; 34: xliii-xlvi.
37. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Kahan BD. Effect of sirolimus on plasma lipids and lipoprotein levels in renal transplant patients (Abstract). Transplantation 1999; 67 (suppl): S60.
38. Chueh S-C J, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus-cyclosporine based immunosuppressive regimen: Incidence, risk factors, and progression, and prognosis. Transplantation 2003; 76: 375.
39. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management. Transplantation 2000; 69: 2085.
40. Kahan BD, Katz SM, Knight RJ. Outcome of 300 renal transplant recipients treated de novo with a sirolimus-cyclosporine regimen at a single center (Abstract 145). Am J Transplant 2001; 1: 172.
41. Kahan BD. Two-year results of multicenter phase III trials of the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003; 35 (suppl): S37.